It is intended to provide an adenosine A
2A
receptor antagonist containing as an active ingredient a thiazole derivative represented by the general formula (I) [in the formula, R
1
represents a substituted or unsubstituted five-membered aromatic heterocyclic group containing at least one oxygen atom, R
2
represents a substituted or unsubstituted heterocyclic group, —COR
6
(in the formula, R
6
represents a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group or the like) or the like, R
3
represents the general formula (II), —NHCOR (in the formula, R
7
represents —NR
8
R
9
or the like) or the like], or a pharmacologically acceptable salt thereof, etc. (I) (II)
该药品旨在提供一种含有腺苷A2A受体拮抗剂的活性成分,该成分为通式(I)所代表的噻唑衍生物[在公式中,R1代表含有至少一个氧原子的取代或未取代的五元芳香杂环基,R2代表取代或未取代的杂环基,-COR6(在公式中,R6代表取代或未取代的杂环基、取代或未取代的芳香杂环基或类似物)或类似物,R3代表通式(II),-NHCOR (在公式中,R7代表-NR8R9或类似物)或类似物],或其药理学上可接受的盐等。(I) (II)
THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER
申请人:Uesaka Noriaki
公开号:US20100152162A1
公开(公告)日:2010-06-17
It is intended to provide an agent for treating and/or preventing sleep disorder containing as an active ingredient a thiazole derivative represented by the general formula (I) (in the formula, R
1
represents a five-membered aromatic heterocyclic group containing at least one oxygen atom or the like, R
2
represents halogen or the like, and R
3
represents —NR
10
R
11
(in the formula, R
10
and R
11
are the same or different and represent a hydrogen atom or the like) or the like) or a pharmacologically acceptable salt thereof.
An adenosine A2A receptor antagonist comprising, as an active ingredient, a thiazole derivative represented by the general formula (I) [wherein R1 represents a substituted or unsubstituted 5-membered aromatic heterocyclic group containing at least one oxygen atom; R2 represents a substituted or unsubstituted heterocyclic group, -COR6 (Wherein R6 represents a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, or the like), or the like; and R3 represents the general formula (II), -NHCOR7 (wherein R7 represents -NR8R9, or the like) or the like] or a pharmaceutically acceptable salt thereof, and the like are provided,